Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

806444

registered interest
date	14/12/2017
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	North Korea: Refugees
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign and Commonwealth Affairs, if he will make representations to the Government of the People's Republic of China on the treatment of refugees from North Korea in China.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119520
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>We remain concerned that China continues to regard North Koreans fleeing the Democratic People's Republic of Korea (DPRK) as economic migrants, and return them to North Korea, rather than as refugees under the 1951 refugee convention. Despite claims by the DPRK authorities that forcibly repatriated refugees are well treated and reintegrated into DPRK society, there are many credible reports, including from the UN Special Rapporteur, that they are often mistreated by the authorities.</p><p>During his 11 December speech at the UN Security Council meeting on the human rights situation in the DPRK, UK Permanent Representative Matthew Rycroft urged all Member States, including China, not to repatriate DPRK refugees. We have asked the Chinese authorities to respect the fundamental principle of non-refoulement and raised the matter at the UK/China Human Rights Dialogue which took place on 27/28 June.</p> answering member constituency Cities of London and Westminster answering member printed Mark Field question first answered 21/12/2017 17:09:17 answering member 1405 label Biography information for Mark Field
tabling member	3958 label Biography information for Fiona Bruce

806466

registered interest
date	14/12/2017
answering body	House of Commons Commission
answering dept id	18
answering dept short name	House of Commons Commission
answering dept sort name	House of Commons Commission
hansard heading	House of Commons: Conditions of Employment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the right hon. Member for Carshalton and Wallington, representing the House of Commons Commission, pursuant to the Answer of 30 November 2017 to Question HL3576, what steps he is taking to strengthen the families of Members and staff working in Parliament.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119542
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The House of Commons Commission is committed to providing family friendly policies, e.g. maternity leave, parental leave, adoption leave, foster care leave, career breaks, flexible working and the offer of Childcare Vouchers.</p><p>The House of Commons Commission has also taken a number of steps to improve the availability of childcare around the Estate. The House Reference Group on Representation and Inclusion is currently piloting an emergency childcare contract, which makes it easier for Members and House staff to find childcare at short notice. This is in addition to the facilities of the Parliamentary nursery, which welcomes users from across the Parliamentary Estate. Also, all Parliamentary pass holders have access to the Westminster Holiday Playscheme catering for children between 4 years 9 months and 12 years old.</p><p>The House of Commons recently launched the Work+Family Space website for Members, Members’ staff and staff of the House of Commons. The site provides assistance with Backup Care services which include Emergency Childcare, School Holiday Cover and Backup Adult &amp; Eldercare, paid for by the end user. The website also offers a range of other services providing information and advice on a range of subjects.</p><p>In addition, Parliament is aiming to take part in the Inter-Parliamentary Union Gender Sensitive Parliament audit. As part of this process there will be a focus on how Parliament supports work-life balance and family obligations.</p><p>The Members’ pension scheme has comprehensive cover for partners, spouses and dependants in the event of a Member’s death, and the benevolent fund can support their families financially if necessary as well, after they have left the House or died.</p> answering member constituency Carshalton and Wallington answering member printed Tom Brake question first answered 21/12/2017 12:51:29 answering member 151 label Biography information for Tom Brake
tabling member	3958 label Biography information for Fiona Bruce

806498

registered interest
date	14/12/2017
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Railways: North West
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what steps his Department is taking to improve rail connectivity between (a) Congleton and Crewe, (b) Congleton and Macclesfield, (c) Congleton and Chester and (d) Congleton and Liverpool.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119574
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>As part of planned improvements to Northern Rail services, there will be a more frequent, hourly Sunday stopping service from Stoke to Manchester via Macclesfield. In the meantime, the Department is happy to work with the local authority and the train operating companies to identify any opportunities to improve rail connectivity for the Congleton area.</p><p> </p> answering member constituency Blackpool North and Cleveleys answering member printed Paul Maynard question first answered 21/12/2017 09:29:27 answering member 3926 label Biography information for Paul Maynard
tabling member	3958 label Biography information for Fiona Bruce

806657

registered interest
date	14/12/2017
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Abortion: Clinics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, how many convictions there have been for public order offences involving vigil participants outside abortion clinics in England and Wales in each of the last five years for which figures are available.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119733
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>This information is not held centrally and can only be provided at disproportionate cost.</p> answering member constituency Esher and Walton answering member printed Dominic Raab question first answered 21/12/2017 15:33:35 answering member 4007 label Biography information for Dominic Raab
tabling member	3958 label Biography information for Fiona Bruce

806660

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what information her Department holds on how many occasions ellaOne, ulipristal acetate 30 mg tablet, has been sold in the UK in 2016.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119736
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>During the time period 1 January 2016 to 31 December 2016, it is estimated that approximately 90,500 tablets of ellaOne 30mg were dispensed against a prescription in pharmacies in the United Kingdom. In addition, it is estimated that there were a further 39,000 tablets of ellaOne 30mg purchased ‘over the counter’ in pharmacies (i.e. without a prescription) in the United Kingdom during the same time period.</p><p> </p><p>This usage data does not capture provision of ellaOne via family planning clinics or stock ordered directly from the manufacturer, via other hospitals or other wholesalers not captured by the database, and therefore some usage for ellaOne will not be included in these figures. For these reasons, the data should be interpreted with caution.</p><p> </p><p>The source of this data is MIDAS Quintiles.</p><p> </p><p>EllaOne is an ulipristal acetate-containing emergency hormonal contraceptive that is licensed for use within five days of unprotected sexual intercourse or contraceptive failure. It is classified as a female emergency contraceptive; it is not an abortifacient. It exerts its contraceptive action by preventing or delaying ovulation. EllaOne has never been studied as an abortifacient. It is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant.</p><p> </p><p>Following a High Court ruling in 2002, emergency contraception is a method of contraception not abortion. The decision confirms the Government’s long held position that a pregnancy begins at implantation and not fertilisation. This judgment means that this position is now established in law and is not a matter of policy.</p><p> </p><p>As with all other licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of ellaOne under close review using a wide number of data sources. These include reports of suspected adverse drug reactions which include pregnancies; spontaneously provided by health professionals and patients through the ‘Yellow Card scheme’. Other sources of data that the MHRA reviews on a regular basis, and which may include information on safety and/or lack of efficacy or inappropriate use, include periodic safety update reports, renewals and variations to product licences. The MHRA also reviews important published medical literature and the results of any new clinical trials or epidemiological studies as they become available.</p><p> </p><p>As with all marketed medicines, the MHRA will continue to monitor the use of ellaOne. In the event that these monitoring processes identify information that suggest that ellaOne is used outside of its licensed indication, advice will be sought from the Commission on Human Medicines and its expert advisory groups. There are post-marketing regulatory measures in place to ensure that ellaOne is used as safely as possible. These measures include a European Union-wide pregnancy registry which collects data on pregnancy outcomes (including pregnancy maintenance and effects on the foetus or newborn) following exposure to ellaOne for any reason. The registry is available at the following link:</p><p><a href="http://www.hra-pregnancy-registry.com" target="_blank">www.hra-pregnancy-registry.com</a></p><p>Women and healthcare professionals involved in the care of pregnant women are asked to report ellaOne exposed pregnancies to the registry via the ellaOne prescribing information and patient leaflet, as well as via yearly letters sent by the marketing authorisation holder. Abortion clinics in particular are requested to ensure that every pregnant woman is asked whether she has taken emergency contraception and if so, to specify which product.</p><p> </p><p>The world-wide data available to date, including data from the EU pregnancy registry, do not suggest any safety concerns following exposure to ellaOne during pregnancy.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119739 119740 question first answered 21/12/2017 16:55:09 answering member 4067 label Biography information for Steve Brine
tabling member	3958 label Biography information for Fiona Bruce

806663

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will undertake a review of the potential abortifacient effect of ellaOne, the ulipristal acetate 30 mg tablet; and if he will make a statement.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119739
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>During the time period 1 January 2016 to 31 December 2016, it is estimated that approximately 90,500 tablets of ellaOne 30mg were dispensed against a prescription in pharmacies in the United Kingdom. In addition, it is estimated that there were a further 39,000 tablets of ellaOne 30mg purchased ‘over the counter’ in pharmacies (i.e. without a prescription) in the United Kingdom during the same time period.</p><p> </p><p>This usage data does not capture provision of ellaOne via family planning clinics or stock ordered directly from the manufacturer, via other hospitals or other wholesalers not captured by the database, and therefore some usage for ellaOne will not be included in these figures. For these reasons, the data should be interpreted with caution.</p><p> </p><p>The source of this data is MIDAS Quintiles.</p><p> </p><p>EllaOne is an ulipristal acetate-containing emergency hormonal contraceptive that is licensed for use within five days of unprotected sexual intercourse or contraceptive failure. It is classified as a female emergency contraceptive; it is not an abortifacient. It exerts its contraceptive action by preventing or delaying ovulation. EllaOne has never been studied as an abortifacient. It is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant.</p><p> </p><p>Following a High Court ruling in 2002, emergency contraception is a method of contraception not abortion. The decision confirms the Government’s long held position that a pregnancy begins at implantation and not fertilisation. This judgment means that this position is now established in law and is not a matter of policy.</p><p> </p><p>As with all other licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of ellaOne under close review using a wide number of data sources. These include reports of suspected adverse drug reactions which include pregnancies; spontaneously provided by health professionals and patients through the ‘Yellow Card scheme’. Other sources of data that the MHRA reviews on a regular basis, and which may include information on safety and/or lack of efficacy or inappropriate use, include periodic safety update reports, renewals and variations to product licences. The MHRA also reviews important published medical literature and the results of any new clinical trials or epidemiological studies as they become available.</p><p> </p><p>As with all marketed medicines, the MHRA will continue to monitor the use of ellaOne. In the event that these monitoring processes identify information that suggest that ellaOne is used outside of its licensed indication, advice will be sought from the Commission on Human Medicines and its expert advisory groups. There are post-marketing regulatory measures in place to ensure that ellaOne is used as safely as possible. These measures include a European Union-wide pregnancy registry which collects data on pregnancy outcomes (including pregnancy maintenance and effects on the foetus or newborn) following exposure to ellaOne for any reason. The registry is available at the following link:</p><p><a href="http://www.hra-pregnancy-registry.com" target="_blank">www.hra-pregnancy-registry.com</a></p><p>Women and healthcare professionals involved in the care of pregnant women are asked to report ellaOne exposed pregnancies to the registry via the ellaOne prescribing information and patient leaflet, as well as via yearly letters sent by the marketing authorisation holder. Abortion clinics in particular are requested to ensure that every pregnant woman is asked whether she has taken emergency contraception and if so, to specify which product.</p><p> </p><p>The world-wide data available to date, including data from the EU pregnancy registry, do not suggest any safety concerns following exposure to ellaOne during pregnancy.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119736 119740 question first answered 21/12/2017 16:55:09 answering member 4067 label Biography information for Steve Brine
tabling member	3958 label Biography information for Fiona Bruce

806664

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Contraceptives: Pregnancy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department plans to conduct controlled studies into the effects of ellaOne in pregnant women; and if he will make a statement.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119740
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>During the time period 1 January 2016 to 31 December 2016, it is estimated that approximately 90,500 tablets of ellaOne 30mg were dispensed against a prescription in pharmacies in the United Kingdom. In addition, it is estimated that there were a further 39,000 tablets of ellaOne 30mg purchased ‘over the counter’ in pharmacies (i.e. without a prescription) in the United Kingdom during the same time period.</p><p> </p><p>This usage data does not capture provision of ellaOne via family planning clinics or stock ordered directly from the manufacturer, via other hospitals or other wholesalers not captured by the database, and therefore some usage for ellaOne will not be included in these figures. For these reasons, the data should be interpreted with caution.</p><p> </p><p>The source of this data is MIDAS Quintiles.</p><p> </p><p>EllaOne is an ulipristal acetate-containing emergency hormonal contraceptive that is licensed for use within five days of unprotected sexual intercourse or contraceptive failure. It is classified as a female emergency contraceptive; it is not an abortifacient. It exerts its contraceptive action by preventing or delaying ovulation. EllaOne has never been studied as an abortifacient. It is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant.</p><p> </p><p>Following a High Court ruling in 2002, emergency contraception is a method of contraception not abortion. The decision confirms the Government’s long held position that a pregnancy begins at implantation and not fertilisation. This judgment means that this position is now established in law and is not a matter of policy.</p><p> </p><p>As with all other licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of ellaOne under close review using a wide number of data sources. These include reports of suspected adverse drug reactions which include pregnancies; spontaneously provided by health professionals and patients through the ‘Yellow Card scheme’. Other sources of data that the MHRA reviews on a regular basis, and which may include information on safety and/or lack of efficacy or inappropriate use, include periodic safety update reports, renewals and variations to product licences. The MHRA also reviews important published medical literature and the results of any new clinical trials or epidemiological studies as they become available.</p><p> </p><p>As with all marketed medicines, the MHRA will continue to monitor the use of ellaOne. In the event that these monitoring processes identify information that suggest that ellaOne is used outside of its licensed indication, advice will be sought from the Commission on Human Medicines and its expert advisory groups. There are post-marketing regulatory measures in place to ensure that ellaOne is used as safely as possible. These measures include a European Union-wide pregnancy registry which collects data on pregnancy outcomes (including pregnancy maintenance and effects on the foetus or newborn) following exposure to ellaOne for any reason. The registry is available at the following link:</p><p><a href="http://www.hra-pregnancy-registry.com" target="_blank">www.hra-pregnancy-registry.com</a></p><p>Women and healthcare professionals involved in the care of pregnant women are asked to report ellaOne exposed pregnancies to the registry via the ellaOne prescribing information and patient leaflet, as well as via yearly letters sent by the marketing authorisation holder. Abortion clinics in particular are requested to ensure that every pregnant woman is asked whether she has taken emergency contraception and if so, to specify which product.</p><p> </p><p>The world-wide data available to date, including data from the EU pregnancy registry, do not suggest any safety concerns following exposure to ellaOne during pregnancy.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119736 119739 question first answered 21/12/2017 16:55:09 answering member 4067 label Biography information for Steve Brine
tabling member	3958 label Biography information for Fiona Bruce

806665

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons guidance for doctors completing the HSA4 form states that recording the NHS number is optional when abortion providers are mandated by the NHS Number Programme Implementation Policy 2008 to record the NHS numbers for their patients.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119741
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>Registered Medical Practitioners (RMP) are legally required, under the Abortion Act 1967, as amended, to notify the Chief Medical Officer of every abortion performed in England and Wales on form HSA4. The forms are used to check that abortions are performed legally and for the compilation of abortion statistics. The recording of the patient’s National Health Service number is not necessary for this purpose. However, the RMP must provide a patient reference number that can identify the patient. This could be the patient’s hospital/clinic number or their NHS number. If a patient reference number is not available, the patient’s full name should be recorded on the HSA4 form.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 21/12/2017 15:57:06 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	3958 label Biography information for Fiona Bruce

806667

registered interest
date	14/12/2017
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Marie Stopes International
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, what recent assessment she has made of her Department's funding to Marie Stopes International in developing countries, in light of the suspension of Marie Stopes’ abortion services in the UK.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119743
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>DFID has robust monitoring and evaluation procedures to ensure UK taxpayers’ money is achieving the results we expect of it. Precise monitoring arrangements vary by project; however progress is always reviewed by DFID, on an annual basis. All of our reviews demonstrate confidence in the quality of MSI’s services in developing countries.</p> answering member constituency Penrith and The Border answering member printed Rory Stewart question first answered 21/12/2017 15:27:17 answering member 4137 label Biography information for Rory Stewart
tabling member	3958 label Biography information for Fiona Bruce

806702

registered interest
date	14/12/2017
answering body	Department for International Development
answering dept id	20
answering dept short name	International Development
answering dept sort name	International Development
hansard heading	Developing Countries: Abortion and Contraceptives
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Development, whether her Department has rejected an application for funding on the grounds that the applicant does not provide abortion and contraception services during the last ten years.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	119778
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>DFID does not withhold funding on the grounds of an organisation's beliefs about reproductive health alone. To be eligible for any specific funding, however, an organisation has to be prepared to deliver the expected outputs of that project, and do so in accordance with the highest standards of evidence.</p> answering member constituency Penrith and The Border answering member printed Rory Stewart question first answered 21/12/2017 15:29:51 answering member 4137 label Biography information for Rory Stewart
tabling member	3958 label Biography information for Fiona Bruce